Imcyse
Imcyse is a clinical-stage biopharmaceutical company that develops a new class of synthetic peptide immunotherapies called Imotopes. These therapies are designed to recalibrate the immune system by breaking abnormal immune responses in patients with severe, chronic autoimmune diseases. The company's current pipeline targets specific indications including Type 1 Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, Neuromyelitis Optica, and Celiac Disease.
Visit websiteLiege, Belgium
Biotechnology
Pharmaceuticals
Healthcare
Funding summary
- Total raised
- €35.0M
- Funding rounds
- 1
Investors in Imcyse
Investors on record for Imcyse. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Imcyse?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors